3rd Quarter - Report

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION

Firm
Client
Income
—
Expenses
$530,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1249 (112th), S. 23 (112th), S. 5369 (112th), H.R. 1706 (112th)

Alcohol and Drug Abuse ALC

Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1316 (112th)

Pharmacy PHA

Reauthorization of the Prescription Drug User Fee Act; Drug Safety

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D/Debt Ceiling

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Health Care Reform; Patent and Affordable Care Act implementation - pricing/rebates; importation; coverage; Independent Patient Advisory Board

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.